Sensitization of cancer chemotherapeutic agents by nitroheterocyclics.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D002330:Carmustine / Q000008:administration & dosage; D002470:Cell Survival / Q000187:drug effects; D004357:Drug Synergism; D006571:Heterocyclic Compounds / Q000008:administration & dosage* / Q000633:toxicity; D006877:Hydroxamic Acids; D000860:Hypoxia; D008130:Lomustine / Q000008:administration & dosage; D008920:Misonidazole / Q000008:administration & dosage / Q000633:toxicity; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000633:toxicity; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000633:toxicity
D006571:Heterocyclic Compounds; D006877:Hydroxamic Acids; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C006358:acetohydroxamic acid; D008130:Lomustine; D008920:Misonidazole; D002330:Carmustine